{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:13:26Z","timestamp":1793643206275,"version":"4.5.1"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a recurring inflammatory skin condition characterized by scaly, red patches on the skin. It affects approximately 3% of the US population and is associated with histological changes such as epidermal hyperplasia, increased blood vessel proliferation, and infiltration of leukocytes into the skin\u2019s dermis. T cells, which are classified into various subtypes, have been found to play significant roles in immune-mediated diseases, particularly psoriasis. This paper provides a review of the different T lymphocyte subtypes and their functions in psoriasis, as well as an overview of targeted therapies for treating psoriasis.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1081256","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T06:09:06Z","timestamp":1698214146000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["The roles of T cells in psoriasis"],"prefix":"10.3389","volume":"14","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/1346-8138.13157","article-title":"Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study","volume":"43","author":"Lopez-Estebaranz","year":"2016","journal-title":"J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3892\/etm.2022.11124","article-title":"Update on the etiopathogenesis of psoriasis (Review)","volume":"23","author":"Branisteanu","year":"2022","journal-title":"Exp Ther Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.me.28.020177.002343","article-title":"Pathophysiology of psoriasis","volume":"28","author":"Voorhees","year":"1977","journal-title":"Annu Rev Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890300039008","article-title":"Long-term safety of cyclosporine in the treatment of psoriasis","volume":"132","author":"Grossman","year":"1996","journal-title":"Arch Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5483\/BMBRep.2022.55.2.183","article-title":"Emerging role of bystander T cell activation in autoimmune diseases","volume":"55","author":"Shim","year":"2022","journal-title":"BMB Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1523-1747.ep12514646","article-title":"Characterization of skin-infiltrating lymphocytes in patients with psoriasis","volume":"96","author":"Nikaein","year":"1991","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122514","article-title":"Models in the research process of psoriasis","volume":"18","author":"Bochenska","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9523628","DOI":"10.1155\/2016\/9523628","article-title":"Thymic and postthymic regulation of naive CD4(+) T-cell lineage fates in humans and mice models","volume":"2016","author":"Belizario","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425677","article-title":"IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human","volume":"35","author":"Vanden Eijnden","year":"2005","journal-title":"Eur J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.003","article-title":"Follicular helper T cells: lineage and location","volume":"30","author":"Fazilleau","year":"2009","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.06.002","article-title":"Phenotype and functions of memory Tfh cells in human blood","volume":"35","author":"Schmitt","year":"2014","journal-title":"Trends Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2016.09.008","article-title":"Altered circulating T follicular helper cell subsets in patients with psoriasis vulgaris","volume":"181","author":"Wang","year":"2017","journal-title":"Immunol Lett"},{"key":"B21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08504.x","article-title":"Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides","volume":"158","author":"Fujimura","year":"2008","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T cells involved in psoriasis vulgaris belong to the Th1 subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J Invest Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.05.046","article-title":"Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis","volume":"135","author":"Harden","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2006.09.008","article-title":"The IL-23\/Th(17) axis: therapeutic targets for autoimmune inflammation","volume":"18","author":"Kikly","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03511.x","article-title":"A role for T cell-derived interleukin 22 in psoriatic skin inflammation","volume":"150","author":"Boniface","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study","volume":"79","author":"Leonardi","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \"T22\" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-009-0194-z","article-title":"Signals that influence T follicular helper cell differentiation and function","volume":"32","author":"Linterman","year":"2010","journal-title":"Semin Immunopathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4927","article-title":"ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells","volume":"177","author":"Bossaller","year":"2006","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.8.5099","article-title":"Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation","volume":"179","author":"Haynes","year":"2007","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088441","article-title":"T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus","volume":"9","author":"Yang","year":"2014","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.intimp.2015.12.037","article-title":"A higher frequency of CD4(+)CXCR5(+) T follicular helper cells in patients with newly diagnosed Henoch-Schonlein purpura nephritis","volume":"32","author":"Zhang","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12162","article-title":"High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis","volume":"174","author":"Wang","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.902149","article-title":"Increased frequency of circulating follicular helper T cells in patients with ankylosing spondylitis","volume":"25","author":"Wu","year":"2015","journal-title":"Mod Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100898108","article-title":"Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers","volume":"108","author":"Bentebibel","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13027","article-title":"Increased circulating follicular helper T cells and activated B cells correlate with disease severity in patients with psoriasis","volume":"29","author":"Niu","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.jid.2021.12.021","article-title":"Transcriptomes of MPO-deficient patients with generalized pustular psoriasis reveals expansion of CD4(+) cytotoxic T cells and an involvement of the complement system","volume":"142","author":"Haskamp","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788940","article-title":"The role of helper T cells in psoriasis","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2005.06538.x","article-title":"Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation","volume":"153","author":"Bovenschen","year":"2005","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5114\/pdia.2014.40920","article-title":"Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis","volume":"31","author":"Nedoszytko","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.010003168.x","article-title":"Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-gamma","volume":"10","author":"Ovigne","year":"2001","journal-title":"Exp Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.426","article-title":"CD8 T Cells and IFN-gamma emerge as critical players for psoriasis in a novel model of mouse psoriasiform skin inflammation","volume":"133","author":"Di Meglio","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B51","article-title":"Reviewing concepts in the immunopathogenesis of psoriasis","volume":"86","author":"Lima Ede","year":"2011","journal-title":"Bras Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.028","article-title":"Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8(+) T cells in autoimmunity and cancer","volume":"147","author":"Liu","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1189\/JLB.0109046","article-title":"IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines","volume":"86","author":"Ortega","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014108","article-title":"Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis","volume":"5","author":"Res","year":"2010","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.4.2878","article-title":"Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven","volume":"166","author":"Costello","year":"2001","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat Commun"},{"key":"B59","article-title":"Proceedings: Evidence for innervation of muscle spindle intrafusal fibres by branches of alpha motoneurones following nerve injury","volume":"238","author":"Brown","year":"1974","journal-title":"J Physiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.05.003","article-title":"Emerging concepts in tissue-resident T cells: lessons from humans","volume":"36","author":"Thome","year":"2015","journal-title":"Trends Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.014","article-title":"From empirical to pathogenesis-based treatments for psoriasis","volume":"142","author":"van de Kerkhof","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br J Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing alphabeta T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of skin resident memory T cells","volume":"11","author":"Tokura","year":"2020","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.02.030","article-title":"Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome","volume":"138","author":"Gallais Serezal","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31202","article-title":"Tregs and rethinking cancer immunotherapy","volume":"117","author":"Curiel","year":"2007","journal-title":"J Clin Invest"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1159\/000238305","article-title":"Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients","volume":"219","author":"Quaglino","year":"2009","journal-title":"Dermatology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3069521","DOI":"10.1155\/2018\/3069521","article-title":"Notch1 signaling regulates the Th17\/Treg immune imbalance in patients with psoriasis vulgaris","volume":"2018","author":"Ma","year":"2018","journal-title":"Mediators Inflamm"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2014.68.236-238","article-title":"Immunophenotype lymphocyte of peripheral blood in patients with psoriasis","volume":"68","author":"Karamehic","year":"2014","journal-title":"Med Arch"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054895","article-title":"Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis","volume":"8","author":"Furuhashi","year":"2013","journal-title":"PloS One"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.11.008","article-title":"Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity","volume":"135","author":"Zhang","year":"2010","journal-title":"Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5021\/ad.2010.22.4.397","article-title":"Role of CD4CD25FOXP3 regulatory T cells in psoriasis","volume":"22","author":"Yun","year":"2010","journal-title":"Ann Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72932","article-title":"Memory regulatory T cells reside in human skin","volume":"124","author":"Sanchez Rodriguez","year":"2014","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1159\/000093849","article-title":"Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in Psoriasis","volume":"213","author":"Bovenschen","year":"2006","journal-title":"Dermatology"},{"key":"B76","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.12236","article-title":"Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin","volume":"168","author":"Keijsers","year":"2013","journal-title":"Br J Dermatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2133.2010.09742.x","article-title":"Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris","volume":"163","author":"Yan","year":"2010","journal-title":"Br J Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jdermsci.2015.11.007","article-title":"Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3","volume":"81","author":"Yang","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064527","article-title":"Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression","volume":"110","author":"Borsellino","year":"2007","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjd.16560","article-title":"Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73\/AMPK\/mTOR pathway","volume":"179","author":"Yan","year":"2018","journal-title":"Br J Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00255","article-title":"Regulation of NKT cell localization in homeostasis and infection","volume":"6","author":"Slauenwhite","year":"2015","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.7.4076","article-title":"Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells","volume":"165","author":"Bonish","year":"2000","journal-title":"J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00151.x","article-title":"The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis","volume":"13","author":"Vissers","year":"2004","journal-title":"Exp Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.5.546","article-title":"Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161","volume":"135","author":"Nickoloff","year":"1999","journal-title":"Arch Dermatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00740-9","article-title":"The role of invariant T cells in inflammation of the skin and airways","volume":"41","author":"Yip","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.261","article-title":"The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells","volume":"134","author":"Teunissen","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/322145a0","article-title":"Identification of a putative second T-cell receptor","volume":"322","author":"Brenner","year":"1986","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.11.040193.003225","article-title":"Gamma\/delta cells","volume":"11","author":"Haas","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.02.018","article-title":"Dermal gammadelta T cells\u2013a new player in the pathogenesis of psoriasis","volume":"16","author":"Cai","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040800","article-title":"Human gammadelta TCR repertoires in health and disease","volume":"9","author":"Fichtner","year":"2020","journal-title":"Cells."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.01.007","article-title":"Thymic determinants of gammadelta T cell differentiation","volume":"38","author":"Munoz-Ruiz","year":"2017","journal-title":"Trends Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100804","article-title":"Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis","volume":"187","author":"Laggner","year":"2011","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"B95","doi-asserted-by":"publisher","first-page":"101569","DOI":"10.1016\/j.tice.2021.101569","article-title":"Glutamine metabolism is essential for the production of IL-17A in gammadelta T cells and skin inflammation","volume":"71","author":"Li","year":"2021","journal-title":"Tissue Cell"},{"key":"B96","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/jdv.13747","article-title":"Predictors of long-term drug survival for infliximab in psoriasis","volume":"31","author":"Magis","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221078203","article-title":"Certolizumab pegol use in the treatment of moderate-to-severe psoriasis: real-world data from two Canadian centers","volume":"26","author":"Vender","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410017275","article-title":"A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab","volume":"15","author":"Scheinfeld","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B101","first-page":"39","article-title":"Biologic treatments of psoriasis: an update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20081463","article-title":"Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis","volume":"206","author":"Conti","year":"2009","journal-title":"J Exp Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1730326","article-title":"The safety of brodalumab for the treatment of psoriasis","volume":"19","author":"Iznardo","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B105","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2174\/187152812800392805","article-title":"The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases","volume":"11","author":"Toussirot","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"B108","doi-asserted-by":"publisher","first-page":"102916","DOI":"10.1016\/j.jaut.2022.102916","article-title":"Pathogenesis, multi-omics research, and clinical treatment of psoriasis","volume":"133","author":"Yu","year":"2022","journal-title":"J Autoimmun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: a review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.gene.2018.09.042","article-title":"Genomic alterations driving psoriasis pathogenesis","volume":"683","author":"Singh","year":"2019","journal-title":"Gene"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1925541","article-title":"JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials","volume":"17","author":"Keeling","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","article-title":"Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis","volume":"19","author":"Torres","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of roflumilast cream for chronic plaque psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15931","article-title":"Tapinarof for the treatment of psoriasis","volume":"35","author":"Nogueira","year":"2022","journal-title":"Dermatol Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215424","article-title":"Aryl hydrocarbon receptor in atopic dermatitis and psoriasis","volume":"20","author":"Furue","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1081256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T06:09:13Z","timestamp":1698214153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1081256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":119,"alternative-id":["10.3389\/fimmu.2023.1081256"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1081256","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"article-number":"1081256"}}